A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

Atrial Fibrillation Clinical Trial

Official title:

A Randomized, Placebo-controlled, Investigator- and Participant-blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04582409
• Other study ID #: CHSY244X2201
• Secondary ID: 2020-004327-17
• Status: Terminated
• Phase: Phase 2
• Start date: November 30, 2020
• Est. completion date: July 11, 2022

Study information

• Verified date: June 2024
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was a randomized, placebo-controlled, investigator- and participant-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of HSY244 in participants with atrial fibrillation (AF), with and without heart failure (HF).

Description:

A screening period of up to 3 days (72 hours) was used to assess eligibility. After eligibility was confirmed, patients were randomized to either HSY244 or placebo. Prior to study drug administration, pre-dose assessments were completed. After the start of study drug administration, the participant was monitored for cardioversion to sinus rhythm. If a participant was still in AF at 90 minutes after the start of study drug administration, direct current cardioversion was planned to be applied at a time deemed appropriate by the investigator.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13
• Est. completion date: July 11, 2022
• Est. primary completion date: July 11, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Key Inclusion Criteria:

• At screening, written informed consent were required to be obtained before any assessment was performed and only participants able to provide written informed consent themselves were included in this study.

• Hemodynamically stable men and women (either of non-child-bearing potential or child bearing potential with highly effective contraception) between 18 and 80 years of age (inclusive) at screening with a clinical indication for direct current cardioversion of AF.

• At screening, current episode of AF had been ongoing for =6 hours and =60 days

• Successful initiation and achievement of therapeutic levels of national guideline and institution-specific anticoagulation therapy as appropriate for the duration of the AF episode and risk for the participant.

• Completion of national guideline and institution-specific imaging evaluation for left atrial thrombi as appropriate for the duration of AF episode and risk for the participant.

• At screening, participants were required to weigh at least 60 kg to participate in the study and were required to have a body mass index (BMI) within the range of 18 - 45 kg/m^2. BMI = Body weight (kg) / [Height (m)]^2

• At screening, vital signs (systolic blood pressure and pulse rate) were assessed in the sitting position. Sitting vital signs were required to be within the following ranges (exclusive):

• systolic blood pressure between 100-160 mmHg and diastolic blood pressure 60-100 mmHg

• pulse rate (ventricular rate) between 60-120 bpm.

Key Exclusion Criteria:

• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they were using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.

• Sexually active males unwilling to use a condom during intercourse while taking investigational drug and for 96 hours after study drug administration. A condom was required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of the investigational drug via seminal fluid to their partner. In addition, male participants could not donate sperm for the time period specified above.

• Use of any anti-arrhythmic class I or III drug (including Ranolazine [Ranexa]) within 5 half lives before randomization; including use of amiodarone within 3 months before randomization.

• At screening, history of current diagnosis of ECG abnormalities or cardiac rhythm disorders as determined by the Investigator's interpretation of the ECG findings indicating a significant risk for participating in the study, such as:

• History of Torsades de Pointes (TdP), any other polymorphic ventricular tachycardia, sustained monomorphic ventricular tachycardia, long QT syndrome, or Brugada syndrome.

• Wolfe-Parkinson-White (WPW) syndrome

• In the absence of a complete bundle branch block a resting QTcF >460 msec for men and >470 msec for women (mean of = 5 consecutive QT intervals)

• In the presence of a complete bundle branch block, a prolonged QTcF or JTc that, in the opinion of the investigator, may pose a risk to patient safety

• Third-degree (complete) heart block, or second-degree Mobitz type II heart block

• Attempted or unsuccessful cardioversion within 2 weeks prior to randomization.

• Presence of known severe mitral regurgitation and/or known severely dilated left atrium.

• Pre-existing or tachycardia-induced moderate to severe cardiac dysfunction (New York Heart Association Class III and IV).

• History within the preceding 3 months prior to randomization of: myocardial infarction, unstable angina, cardiac surgery, or a percutaneous coronary intervention.

• History of a confirmed stroke or transient ischemic attack (TIA).

• History or current diagnosis of any seizure disorder, epilepsy, significant head trauma, or other disorders increasing the risk for seizures.

• History or current diagnosis of a major neurologic or psychiatric disorder that, in the opinion of the investigator, poses a risk to patient safety to participate.

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Drug:
• HSY244
HSY244 concentrate solution for injection via intravenous infusion

Other:
• Placebo
Placebo concentrate solution for injection via intravenous infusion

Locations

Country	Name	City	State
Germany	Novartis Investigative Site	Bad Oeynhausen
Germany	Novartis Investigative Site	Frankfurt
United States	Novartis Investigative Site	Boston	Massachusetts
United States	Novartis Investigative Site	Lansing	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Conversion to Sinus Rhythm for at Least 1 Minute Within 90 Minutes From the Start of Study Drug Administration.	Conversion to sinus rhythm was monitored using a Holter monitoring device through 90 minutes after the start of study drug administration.; If a participant had been monitored for at least 45 minutes and did not convert to sinus rhythm for at least one minute, the primary endpoint was defined as 'no'. If a participant converted to sinus rhythm for at least one minute at any time during the post-treatment 90 minutes observation period, regardless of the length of time monitored, the primary endpoint was to be defined as 'yes'.	90 minutes from the start of study drug administration
Secondary	Maximum Observed Plasma Concentration (Cmax)	The Cmax is the maximum (peak) observed plasma drug concentration after single-dose administration.; Actual recorded sampling times were taken into consideration for PK calculations.	Day 1 (0 min (pre-dose), 15 min (end of infusion), 30 min , 60 min, 90 min and 180 min) and Day 5
Secondary	Time to Reach the Maximum Concentration After Drug Administration (Tmax)	Tmax is the time to reach maximum (peak) plasma drug concentration after single dose administration (time).; Actual recorded sampling times were taken into consideration for PK calculations.	Day 1 (0 min (pre-dose), 15 min (end of infusion), 30 min , 60 min, 90 min and 180 min) and Day 5
Secondary	Area Under the Plasma Concentration-time Curve (AUClast)	AUClast is the AUC from time zero to the last measurable concentration sampling time (tlast).; Actual recorded sampling times were taken into consideration for PK calculations.	Day 1 (0 min (pre-dose), 15 min (end of infusion), 30 min , 60 min, 90 min and 180 min) and Day 5

External Links

•   Patient Lay Trial Summary
•   Results for CHSY244X2201 that is getting linked from the Novartis Clinical Trials Website